Table 2 Tumor and pathologic response to neoadjuvant chemo-immunotherapy

From: Tislelizumab (anti-PD-1) plus chemotherapy as neoadjuvant therapy for patients with stage IB3/IIA2 cervical cancer (NATIC): a prospective, single-arm, phase II study

Clinical response to neoadjuvant immunochemotherapy

Patients (n = 30)

Imaging-based response per RECIST v.1.1

Objective response

27 (90.0%)

Best overall response

Complete response

17 (56.7%)

Partial response

10 (33.3%)

Stable disease

3 (10.0%)

Progressive disease

0

Pathologic response

Optimal pathologic response

24 (80.0%)

Pathologic complete response

20 (66.7%)

Major pathologic response

4 (13.3%)

Non-optimal pathologic response

6 (20.0%)

  1. Data are n (%). RECIST Response Evaluation Criteria in Solid Tumors, version 1.1
Back to article page